Salute e Benessere
FDA approves Novo Nordisk's oral semaglutide for cardiovascular (CV) risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event
This new indication makes Rybelsus the only oral GLP-1 medicine approved to reduce the risk of MACE in adults with type 2 diabetes who are at high risk for these events. It serves for both primary prevention (reducing the risk of major adverse cardiovascular events by preventing or managing risk factors in adults who are at high risk for these events) and secondary prevention (reducing the risk of another event in people who have had a serious CV event).
The primary objective of the phase 3b SOUL trial was to evaluate the effects of oral semaglutide 14 mg, in addition to standard of care, on reducing the risk of MACE in adults with type 2 diabetes at high risk for major cardiovascular events. The primary endpoint of the study was the time to first occurrence of MACE (a 3-point composite of CV death, non-fatal myocardial infarction, or nonfatal stroke). MACE events occurred in 579/4825 participants (12.0%) of the semaglutide group and 668/4825 participants (13.8%) of the placebo group (HR 0.86; 95% CI, 0.77-0.96; p=0.006). Oral semaglutide 14 mg demonstrated a statistically significant 14% relative reduction in risk of MACE at 4 years (2% absolute risk reduction at 3 years) compared with placebo. These results add to the extensive body of randomized clinical trial and real-world evidence supporting semaglutide.
"As the only FDA-approved GLP-1 therapy in a pill, now recognized for its proven cardiovascular benefits, a new benchmark has been set for future oral innovations," said Dave Moore , Executive Vice President, US Operations of Novo Nordisk Inc. "The semaglutide molecule has consistently demonstrated robust outcomes across multiple, large-scale trials, further reinforcing the already established cardiovascular profile it delivers for patients."
The overall safety profile of oral semaglutide 14 mg in SOUL was consistent with that seen in previous trials, with safety data collection focused on serious adverse events, those of special interest, and those leading to discontinuation. The most common serious adverse events (SAEs) in the oral semaglutide 14 mg and placebo groups were cardiac disorders (17.8% and 19.8%, respectively) and infections/infestations (15.0% and 16.5%, respectively). SAEs were less common with oral semaglutide 14 mg (47.9%) than with placebo (50.3%), although there was a higher incidence of gastrointestinal disorders with oral semaglutide 14 mg (5.0% versus 4.4%). Adverse events that led to permanent discontinuation of oral semaglutide or placebo occurred in 749 participants (15.5%) in the oral semaglutide group and in 559 participants (11.6%) in the placebo group. Such events were mainly gastrointestinal disorders as well as infections or infestations.
The FDA initially approved Rybelsus in 2019 as the first and only GLP-1 medicine in pill form, along with diet and exercise, to improve glycemic control for adults with type 2 diabetes.
Separately, Novo Nordisk has also submitted a supplemental application in the US for a once-daily oral formulation of semaglutide under the trade name Wegovy for the treatment of obesity. A decision is expected later this year.
Only Novo Nordisk manufactures FDA-approved semaglutide medicines. Novo Nordisk is continuing to take multiple proactive measures to prevent both unlawful compounded and counterfeit versions of semaglutide. Novo Nordisk believes it is vitally important to make patients aware of the potential dangers of these unsafe and unapproved knockoff alternatives and informed of how to access authentic, FDA-approved Novo Nordisk semaglutide medicines. More information can be found on semaglutide.com.
SOUL was a multicenter, international, randomized, double-blind, parallel-group, placebo-controlled, phase
3b cardiovascular outcomes trial, with 9,650 participants enrolled. It was conducted to assess the effect of oral semaglutide versus placebo, when added to standard of care, on cardiovascular outcomes in people with type 2 diabetes who are at high risk of MACE (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke). The SOUL trial was initiated in 2019 with a mean follow up of 4 years. The primary outcome was time-to-first occurrence of major adverse cardiovascular events (MACE; a composite endpoint consisting of cardiovascular death, heart attack, and stroke). Oral semaglutide 14 mg demonstrated a statistically significant 14% relative reduction in risk of MACE at 4 years (2% absolute risk reduction at 3 years) compared with placebo.
Rybelsus (oral semaglutide) is a GLP-1 receptor agonist indicated for the treatment of adults with type 2 diabetes mellitus to improve glycemic control as an adjunct to diet and exercise. Rybelsus is administered once daily and is currently available for use in two therapeutic dosages: 7 mg and 14 mg. Rybelsus is currently commercially marketed in 45 countries. 2.4 million people have been prescribed Rybelsus worldwide.
RYBELSUS (semaglutide) tablets 7 mg or 14 mg is a prescription medicine used:
It is not known if RYBELSUS is safe and effective for use in children
including prescription and over-the-counter medicines, vitamins, and herbal supplements. RYBELSUS may affect the way some medicines work and some medicines may affect the way RYBELSUS works.
nausea, stomach (abdominal) pain, diarrhea, decreased appetite, vomiting, and constipation. Nausea, vomiting, and diarrhea are most common when you first start RYBELSUS .
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2025 Novo Nordisk All rights reserved. US25RYB00345 October 2025
Logo - https://mma.prnewswire.com/media/2751477/novo_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/fda-approves-novo-nordisks-oral-semaglutide-for-cardiovascular-cv-risk-reduction-in-adults-with-type-2-diabetes-who-are-at-high-risk-including-those-who-have-not-had-a-prior-cv-event-302588022.html